ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV
Acerta Pharma BV
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Ohio State University Comprehensive Cancer Center